蜂窝织炎试验报告哪些结局?结局综述与患者优先事项调查
该研究综述了治疗与预防蜂窝织炎的随机对照试验(RCT)所用的结局指标,并结合蜂窝织炎优先事项设定伙伴关系(PSP)调查中患者与医护人员的反馈。结果显示结局指标异质性显著、患者报告结局关注不足,且当前测量与患者及医护人员认为重要的内容存在差距。
要点
- 蜂窝织炎RCT结局指标异质性大,临床应答分类多达25种。
- 仅少数试验纳入生活质量或患者满意度,患者报告结局不足。
- 患者最重视预防复发、临床特征与长期疾病影响。
核心结论
- 蜂窝织炎治疗与预防试验的临床结局存在显著异质性,患者报告结局关注不足,当前测量与患者及医护人员认为重要的内容存在差距。
- 建议未来蜂窝织炎治疗试验考虑采用长期结局以捕捉复发和长期疾病负担,同时关注急性感染的短期缓解。
研究设计与样本
- 综述了来自两项近期Cochrane综述中RCT的所有结局指标。
- 纳入42项蜂窝织炎治疗RCT与6项预防RCT的结局。
- 采用蜂窝织炎优先事项设定调查的自由文本反馈了解患者与医护人员视角。
主要发现
- 42项治疗RCT与6项预防RCT的结局被综述,仅28项试验报告了主要结局。
- 治疗试验中临床应答分类有25种不同方式,仅5项试验使用符合FDA指南的结局,仅4项试验纳入生活质量或患者满意度。
- 预防试验的关键结局指标为复发。
- PSP调查显示患者最重要的结局主题为预防复发、临床特征与长期疾病影响。
关键数值与推荐
- 治疗试验中临床应答分类达25种不同方式。
- 仅5项治疗试验使用符合FDA指南的结局。
- 仅4项试验纳入生活质量或患者满意度。
临床怎么用
- 未来蜂窝织炎治疗试验应同时评估急性感染短期缓解与长期复发及长期疾病负担。
- 试验设计应更多纳入患者报告结局,如生活质量与患者满意度。
局限性
- 原文未报告
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: There is an emerging need to develop consistent outcomes in clinical trials to allow effective comparison of treatment effects. No systematic review has previously looked at the reporting of outcome measures used in randomized controlled trials (RCTs) on the treatment and prevention of cellulitis (erysipelas). OBJECTIVES: The primary aim of this review was to describe the breadth of outcomes reported from RCTs on cellulitis treatment and prevention. The secondary aim was to identify outcome themes from patients' and healthcare professionals' feedback from a cellulitis Priority Setting Partnership (PSP). METHODS: We conducted a review of all outcome measures used in RCTs from two recent Cochrane reviews. Free-text responses from a cellulitis priority setting survey were used to understand the perspectives of patients and healthcare professionals. RESULTS: Outcomes from 42 RCTs on treatment of cellulitis and six RCTs on prevention of cellulitis were reviewed. Only 28 trials stated their primary outcome. For trials assessing treatment of cellulitis, clinical response to treatment was categorized in 25 different ways. Five of these trials used an outcome that was in accordance with FDA guidance and only four trials incorporated either quality of life or patient satisfaction. For trials assessing prevention of cellulitis, recurrence was the key outcome measure. From the cellulitis PSP, prevention of recurrence, clinical features and long-term disease impact were the most important outcome themes for patients. CONCLUSIONS: We have shown that in cellulitis treatment and prevention research, there is significant heterogeneity in clinical outcomes, inadequate focus on patient-reported outcomes, and a disparity between what is currently measured and what patients and healthcare professionals feel is important. We recommend that future cellulitis treatment trials consider the use of longer-term outcomes to capture recurrence and long-term morbidity, as well as short-term resolution of acute infection.
引用
- Smith E, Patel M, Thomas KS, et al. Which outcomes are reported in cellulitis trials? Results of a review of outcomes included in cellulitis trials and a patient priority setting survey. Br J Dermatol. 2018. PMID: 29222939. doi:10.1111/bjd.16235
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。